Related references
Note: Only part of the references are listed.GMP manufacturing of Vvax001, a therapeutic anti-HPV vaccine based on recombinant viral particles
Annelies Jorritsma-Smit et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Bystander IFN-γ activity promotes widespread and sustained cytokine signaling altering the tumor microenvironment
Ronan Thibaut et al.
NATURE CANCER (2020)
The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
Diane M. Harper et al.
GYNECOLOGIC ONCOLOGY (2019)
MHC-II neoantigens shape tumour immunity and response to immunotherapy
Elise Alspach et al.
NATURE (2019)
Cytokines in clinical cancer immunotherapy
Pedro Berraondo et al.
BRITISH JOURNAL OF CANCER (2019)
An alphavirus-based therapeutic cancer vaccine: from design to clinical trial
Amrita Singh et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Therapeutic vaccines for high-risk HPV-associated diseases
Aleyo Chabeda et al.
PAPILLOMAVIRUS RESEARCH (2018)
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
Nisha Nagarsheth et al.
NATURE REVIEWS IMMUNOLOGY (2017)
Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response
Mariette I. E. van Poelgeest et al.
CLINICAL CANCER RESEARCH (2016)
Detection of HPV-associated oropharyngeal tumours in a 16-year cohort: more than meets the eye
L. J. Melchers et al.
BRITISH JOURNAL OF CANCER (2015)
Antigen design enhances the immunogenicity of Semliki Forest virus-based therapeutic human papillomavirus vaccines
P. P. Ip et al.
GENE THERAPY (2015)
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L. Trimble et al.
LANCET (2015)
Self-replicating alphavirus RNA vaccines
Karl Ljungberg et al.
EXPERT REVIEW OF VACCINES (2015)
Alphavirus-based Vaccines Encoding Nonstructural Proteins of Hepatitis C Virus Induce Robust and Protective T-cell Responses
Peng Peng et al.
MOLECULAR THERAPY (2014)
Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients
Tae Jin Kim et al.
NATURE COMMUNICATIONS (2014)
A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer
Susan F. Slovin et al.
VACCINE (2013)
CD4+ T-cell response against human papillomavirus type 16 E6 protein is associated with a favorable clinical trend
Kevin H. Kim et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses
Mark L. Bagarazzi et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies
Joseph E. Tota et al.
PREVENTIVE MEDICINE (2011)
CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes
Rinke Bos et al.
CANCER RESEARCH (2010)
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer
Michael A. Morse et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
A Favorable Clinical Trend Is Associated With CD8 T-Cell Immune Responses to the Human Papillomavirus Type 16 E6 Antigens in Women Being Studied for Abnormal Pap Smear Results
Mayumi Nakagawa et al.
JOURNAL OF LOWER GENITAL TRACT DISEASE (2010)
Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens
Annechien J. A. Lambeck et al.
VACCINE (2010)
Papillomaviruses in the causation of human cancers - a brief historical account
Harald zur Hausen
VIROLOGY (2009)
Induction of tumor-specific CD4+ and CD8+ T-Cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine
Marij J. P. Welters et al.
CLINICAL CANCER RESEARCH (2008)
Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells
S. B. Justin Wong et al.
JOURNAL OF IMMUNOLOGY (2008)
Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition
A. de Mare et al.
GENE THERAPY (2008)
A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer
A. Riezebos-Brilman et al.
GENE THERAPY (2007)
Human papillomavirus and cervical cancer
Mark Schiffman et al.
LANCET (2007)
Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III
Mark H. Einstein et al.
GYNECOLOGIC ONCOLOGY (2007)
The natural history of cervical HPV infection: unresolved issues
Ciaran B. J. Woodman et al.
NATURE REVIEWS CANCER (2007)
Assessment of gene promoter hypermethylation for detection of cervical neoplasia
G. Bea A. Wisman et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Recombinant alphaviruses as vectors for anti-tumour and anti-microbial immunotherapy
A Riezebos-Brilman et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
ZYC101a for treatment of high-grade cervical intralepithelial neoplasia: A randomized controlled trial
F Garcia et al.
OBSTETRICS AND GYNECOLOGY (2004)
Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+T-cell immunity against early antigens E2 and E6
A de Jong et al.
CANCER RESEARCH (2004)
Requirement for CD4 T cell help in generating functional CD8 T cell memory
DJ Shedlock et al.
SCIENCE (2003)
Eradication of established HPV16-transformed tumours after immunisation with recombinant Semliki Forest virus expressing a fusion protein of E6 and E7
T Daemen et al.
VACCINE (2003)
CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes
EM Janssen et al.
NATURE (2003)
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
JJM van Dongen et al.
LEUKEMIA (2003)
Vaccination with recombinant alphavirus or immune-stimulating complex antigen against respiratory syncytial virus
M Chen et al.
JOURNAL OF IMMUNOLOGY (2002)
Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7
T Daemen et al.
GENE THERAPY (2002)
Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens
M Nakagawa et al.
JOURNAL OF INFECTIOUS DISEASES (2000)
Share Paper
